Hadean Ventures

VCMatch tracks Hadean Ventures as an investor focused on Biotech, Pharma, and Medtech companies, Pre-Seed and Seed rounds, and Europe and United States markets. Upload your deck to compare your startup against the full private matching profile.

Check Size

Not specified

Stages

Pre-Seed, Seed, Series A, Series B, Series C, Growth, Late Stage

Focus Areas

Biotech, Pharma, Medtech

Geography

Europe and United States

Investment Thesis

Hadean Ventures positions itself as a European life-science specialist investing in “the future of healthcare.” They take a domain-driven, impact-oriented approach: investing across healthcare verticals and stages in products that can “address unmet medical needs,” while combining deep medical/scientific expertise with hands-on operational support to help companies commercialize and scale.

Is Hadean Ventures right for your startup?

Upload your pitch deck to compare your startup against VCMatch's private investor profile, including fit, timing, and next-step signals.

See If You're a Match View Sample Match

Investment Focus

Who should take a closer look

Hadean Ventures is most relevant for founders raising Pre-Seed, Seed, and Series A rounds in Biotech, Pharma, Medtech, and Healthtech, especially across Europe and United States.

Focus statement

"We invest across all healthcare verticals and stages, in products with the potential to address unmet medical needs." Hadean is a Europe-based life science VC (c. EUR 230m AUM) that backs technologies and therapeutics with clear clinical or commercial inflection potential.

Value Add

"c. EUR 230m assets under management" — a dedicated European life-science fund size that signals sector focus and capacity for follow-on capital.
Domain and clinical depth: "Our team combines an in-depth knowledge of medicine and life science, extensive investment experience at prestigious venture capital funds, and a strong track record of hands-on operational management of start-ups." (large team of MDs, PhDs, and senior pharma executives/advisors).
Stage-agnostic, sector-wide mandate: explicit coverage of "all healthcare verticals and stages," allowing flexibility to lead or participate across seed to growth.
Operational support and commercialization focus — example: led Hadean-backed Series A for Ribbon Biolabs to enable "commercial scale production facilities and US expansion," showing focus on enabling scale and market entry.
ESG/impact integration: presence of an "Impact & ESG Manager" on the team indicates explicit attention to sustainability/impact considerations in investment processes.
Active life-science network: senior advisors with drug/device development and pharma executive track records (e.g., Bernd Seizinger, Denise Barbut, Duncan Moore) provide technical, clinical and go-to-market experience.